Abstract
Abstract
Purpose
Gastrointestinal cancers, including colorectal cancer (CRC), gastric cancer (GC), and esophageal cancer (EC), are among the most common and lethal malignancies worldwide. Early detection is critical for improving patient outcomes, but the current diagnostic methods, such as endoscopy, are burdensome, costly, and inaccessible for widespread screening. Here, we have identified the transformative potential of non-invasive blood-based diagnostics by integrating advanced glycan biomarkers and machine learning.
Experimental design
This study analyzed serum samples from 296 CRC, 180 GC, and 42 EC patients, alongside 590 healthy controls. Nine conventional tumor markers were quantified and 1688 enriched glycopeptides (EGPs) were identified via liquid chromatography-mass spectrometry. Using Comprehensive Serum Glycopeptide Spectrum Analysis (CSGSA), EGPs were integrated with conventional markers into machine learning models, including neural networks, to develop and validate diagnostic frameworks.
Results
Two glycopeptides, α1-antitrypsin at Asn271 and α2-macroglobulin at Asn70, were identified as highly cancer-specific biomarkers. Integrating these glycopeptides, tumor markers, and EGPs significantly improved the diagnostic performance. The neural network-based model achieved area under the curve values of 0.966, 0.992, and 0.995 for CRC, GC, and EC, respectively, with respective positive predictive values of 54.5 %, 35.3 %, and 11.1 %, exceeding non-invasive diagnostic benchmarks. Remarkably, the CSGSA approach differentiated cancer types with high accuracy, even in early-stage disease.
Conclusion
CSGSA represents a breakthrough in non-invasive gastrointestinal cancer diagnostics, combining glycopeptide profiling with machine learning to achieve unprecedented accuracy. This method provides a cost-effective and scalable alternative to invasive procedures and may have potential utility in general health screening, which warrants further investigation.